News
COVID-19 and clinical trials : point of view of Luc Feldmann
COVID-19 and clinical trials : point of view of Luc Feldmann In light of the exceptional situation surrounding COVID-19, CATALIS interviewed clinical research leaders in Quebec to find out their perspectives on the crisis and to look for ways to adapt. The following statements detail the point of view of Luc Feldmann, Director, International Centre of Therapeutic Research, Servier Canada.
COVID-19 and clinical trials : point of view of Angela Genge
In light of the exceptional situation surrounding COVID-19, CATALIS interviewed clinical research leaders in Quebec to find out their perspectives on the crisis and to look for ways to adapt. The following statements detail the point of view of Dr. Angela Genge, Neurologist and Director, Clinical Research Unit, Montreal Neurological Institute-Hospital.
COVID-19 and clinical trials : point of view of Dr. Gerald Batist
In light of the exceptional situation surrounding COVID-19, CATALIS interviewed clinical research leaders
in Quebec to find out their perspectives on the crisis and to look for ways to adapt. The following
statements detail the point of view of Dr. Gerald Batist, Deputy Director and Senior Investigator, Jewish
General Hospital’s Lady Davis Institute.
COVID-19 and clinical trials : point of view of Vatche Bartekian
In light of the exceptional situation surrounding COVID-19, CATALIS interviewed clinical research leaders in Quebec to find out their perspectives on the crisis and look for ways to adapt. The following statements detail the point of view of Vatche Bartekian, President of Vantage BioTrials Inc.
COVID-19 and clinical trials : point of view of Marc Rivière
In light of the exceptional situation surrounding COVID-19, CATALIS interviewed clinical research leaders in Quebec to find out their perspectives on the crisis and look for ways to adapt. The following statements detail the point of view of Marc Rivière, Chief Medical Officer, TVM Capital and Chairman of the Board of Directors, CATALIS Québec.
CATALIS Québec applauds the Quebec Government’s commitment to clinical research
The Quebec Government’s 2020–2021 budget, tabled yesterday by Minister of Finance Éric Girard, mentions investments in the field of clinical research, a commitment that was favourably received by CATALIS Québec’s board of directors.
CATALIS Québec Partners with The Coolest Hotspot Initiative
Quebec is a top destination for life sciences and clinical research. To strengthen our efforts to spread this message beyond Quebec, CATALIS Québec has joined The Coolest Hotspot network.
A clinical trial to improve pancreatic cancer treatment
A team from the CHU de Québec-Université Laval has begun a clinical trial in order to develop new therapeutic options for the treatment of pancreatic adenocarcinoma, an aggressive cancer whose survival rate is less than one year.
Solutions to Stimulate Clinical Research in Quebec
2020 promises to be a pivotal year for the rise of clinical research in Quebec. With our partners and sector stakeholders, we are taking concrete steps towards making Quebec an authority in the clinical trial sector.
Number of early-stage clinical studies at the CHU de Québec Research Centreabout to double
The CHU de Québec-Université Laval (CRCHU) Research Centre has worked extra hard this year to stimulate launches of early-stage clinical research projects in the Quebec City region. The Research Centre is about to double the number of clinical trials conducted in its institutions.